Checkpoint Therapeutics’ (CKPT) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note published on Thursday morning,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.

Checkpoint Therapeutics Stock Performance

Shares of Checkpoint Therapeutics stock traded down $0.32 during trading on Thursday, hitting $3.46. The company’s stock had a trading volume of 656,303 shares, compared to its average volume of 522,220. Checkpoint Therapeutics has a 52 week low of $1.36 and a 52 week high of $3.97. The company has a fifty day simple moving average of $2.79 and a two-hundred day simple moving average of $2.33. The company has a market capitalization of $155.77 million, a PE ratio of -1.92 and a beta of 1.23.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). As a group, analysts predict that Checkpoint Therapeutics will post -0.81 EPS for the current year.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several large investors have recently modified their holdings of CKPT. Walleye Capital LLC bought a new stake in Checkpoint Therapeutics during the 3rd quarter valued at about $148,000. Gladstone Institutional Advisory LLC increased its position in shares of Checkpoint Therapeutics by 141.4% during the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 20,500 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Checkpoint Therapeutics by 160.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after acquiring an additional 80,000 shares during the last quarter. Magnus Financial Group LLC lifted its position in Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 4,000 shares in the last quarter. Finally, PVG Asset Management Corp bought a new position in Checkpoint Therapeutics in the 2nd quarter valued at approximately $295,000. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.